Citius Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of critical care products. Its LYMPHIR, an FDA approved product, is a targeted immunotherapy for the treatment of cutaneous T-cell lymphoma. The company's late-stage pipeline includes Mino-Lok, an antibiotic lock solution to salvage catheters in patients with catheter-related bloodstream infections; and CITI-002 (Halo-Lido), a topical formulation for the relief of hemorrhoids. The Pivotal Phase 3 Trial for Mino-Lok and a Phase 2b trial for Halo-Lido completed. Citius Pharmaceuticals, Inc. was founded in 2007 and is headquartered in Cranford, New Jersey.

Citius Pharmaceuticals Inc.

Citius Pharmaceuticals ( ($CTXR) ) just unveiled an announcement. On March 10, 2026, Citius Oncology reported positive topline results from an inve...

Current Yield	N/A	Payout Ratio	N/A
Annual DPS	$0.00	Growth Streak	0 years
Ex-Dividend	Invalid Date	Pay Date	Invalid Date
Record Date	N/A	Declaration	N/A
Frequency	NA	Quarterly Est	$0.00

	A	B	C	D
1	Symbol	Price	Change	Volume
2	CTXR	$0.83	+4.65%	244.93K
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	CTXR	$0.83	+4.6%	244.93K
3
4
5
6

CTXR

CTXR

Dividend Overview

Get Citius Pharmaceuticals Inc. Data in Excel

Get Citius Pharmaceuticals Inc. Data in Excel